EXTON, Pa., Oct. 1, 2015 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that John Maslowski, Senior Vice President of Scientific Affairs, will present on Thursday, October 8 at 4:45 p.m. PDT at the annual Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 7-9 in La Jolla, California.
This regenerative medicine conference brings together senior executives and top decision makers from the industry's scientific community with the goal of advancing and translating cutting-edge research into potential treatments and cures.
Mr. Maslowski's presentation will be webcast live under the Investors & Media section of Fibrocell's website at fibrocell.com/investors/events-and-presentations, and also posted on the Alliance for Regenerative Medicine's (ARM) website shortly after the event. Please visit Fibrocell's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
Co-hosted by ARM, the California Institute for Regenerative Medicine (CIRM) and the Sanford Consortium for Regenerative Medicine, the 2015 Stem Cell Meeting on the Mesa is a three-day conference featuring a two-day Partnering Forum, a Public Forum Lecture and a full-day Scientific Symposium.
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (NASDAQ:FCSC) is an autologous cell and gene therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell's most advanced product candidate, azficel-T, uses its proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring. In collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is also developing gene therapies for skin diseases using gene-modified autologous fibroblasts. Fibrocell is in preclinical development of FCX-007, its orphan gene-therapy product candidate, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is also in preclinical development of FCX-013, its second gene-therapy product candidate, for the treatment of linear scleroderma. For more information, visit fibrocell.com.
CONTACT: Investor & Media Relations Contact: Karen Casey Fibrocell Science, Inc. +1 (484) 713-6133 email@example.comSource:Fibrocell Science, Inc.